Traditionally viewed as major cellular components in hemostasis and thrombosis, the
contribution of platelets to the progression of cancer is an emerging area of research …

Thrombosis is the most frequent complication and the second cause of death in patients with
overt malignant disease. Increasing evidence suggests that thrombotic episodes may also …

The purpose of this brief survey is to outline the development of knowledge on the
interactions between the hemostatic system and malignant diseases. Special emphasis will …

The purpose of this review is to demonstrate the potential for development of coagulation-
reactive drugs for experimental cancer treatment. Improved cancer outcome has been …

Cellular sites of coagulation activation within complex, intact tissues have been studied by
immunohistochemical techniques. Hirudin, a specific and high affinity inihibitor of the active …

In this introductory chapter a story has been reviewed concerning the evolution of the
concept of “cancer and thrombosis”, since its first description by Armand Trousseau in 1865 …

Fig. 1 Panel a. Specific staining by the peroxidase reaction using diaminobenzidine as
substrate (that gave a brown color reaction) and monospecific polyclonal antibody to hepsin …

This overview of the coagulation biology of cancer is intended primarily for those unfamiliar
with the link between the coagulation mechanism and neoplasia. Because the literature on …

In oncotherapy, ruthenium complexes are considered as potential alternatives for platinum
compounds, and have been proved as promising anticancer drugs with high efficacy and …

It has been known for over a century that blood coagulation and fibrinolysis pathways are
activated systemically in patients with malignancy. Recent studies have revealed evidence …